Abstract

Cationic Lipids Offer New Possibilities in Liposome and LNP Engineering for RNA Therapeutics

Jean-Thomas Issenhuth, Key Account Manager EMEA, Polyplus-Transfection

Lipid-based nanoparticles (LNPs) represent one of the most promising RNA delivery systems, not only due to their efficacy, but also to the ease of production achieved through precise controlled mixing technique known as microfluidics and the scalability of production. Still, they present some limitations related to toxicity, targeting, limited biodistribution through systemic administration which mainly results in liver uptake. Polyplus^® has recently developed a library of cationic lipids (LipidBrick^®), which represents a remarkable innovation compared with conventional cationic lipids by ensuring reduced toxicity of LNPs and extending their use beyond the liver.